EA200901031A1 - Модуляторы склеростин-связывающих партнеров для лечения костных расстройств - Google Patents

Модуляторы склеростин-связывающих партнеров для лечения костных расстройств

Info

Publication number
EA200901031A1
EA200901031A1 EA200901031A EA200901031A EA200901031A1 EA 200901031 A1 EA200901031 A1 EA 200901031A1 EA 200901031 A EA200901031 A EA 200901031A EA 200901031 A EA200901031 A EA 200901031A EA 200901031 A1 EA200901031 A1 EA 200901031A1
Authority
EA
Eurasian Patent Office
Prior art keywords
sclerostin
bone
treatment
modulators
disorders
Prior art date
Application number
EA200901031A
Other languages
English (en)
Inventor
Крис Сянян Лю
Шуих Сюй
Михаэла Кнайссель
Кристине Аллёкс
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA200901031A1 publication Critical patent/EA200901031A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders

Abstract

В заявке описано применение модуляторов взаимодействия склеростин:склеростин-связывающий партнер для лечения, облегчения и диагностики расстройств, связанных со склеростином, например остеопороза и склеростеоза, и расстройств, связанных со склеростином, например рака и сердечно-сосудистых расстройств. В заявке также описано применение миметиков склеростин-связывающего партнера для лечения, облегчения и диагностики склеростин-связанных расстройств. Также предусмотрены исследования по идентификации модуляторов взаимодействия склеростин:склеростин-связывающий партнер, а также возникающей передачи сигнала.
EA200901031A 2007-02-02 2008-01-30 Модуляторы склеростин-связывающих партнеров для лечения костных расстройств EA200901031A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88795607P 2007-02-02 2007-02-02
PCT/EP2008/051128 WO2008092894A1 (en) 2007-02-02 2008-01-30 Modulators of sclerostin binding partners for treating bone-related disorders

Publications (1)

Publication Number Publication Date
EA200901031A1 true EA200901031A1 (ru) 2010-04-30

Family

ID=39298321

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200901031A EA200901031A1 (ru) 2007-02-02 2008-01-30 Модуляторы склеростин-связывающих партнеров для лечения костных расстройств

Country Status (16)

Country Link
US (3) US20100028335A1 (ru)
EP (1) EP2114435A1 (ru)
JP (1) JP2010526766A (ru)
KR (1) KR20090115133A (ru)
CN (1) CN101616684A (ru)
AU (1) AU2008209713B2 (ru)
BR (1) BRPI0807205A2 (ru)
CA (1) CA2675639A1 (ru)
EA (1) EA200901031A1 (ru)
IL (1) IL199834A0 (ru)
MA (1) MA31156B1 (ru)
MX (1) MX2009008096A (ru)
NZ (1) NZ578235A (ru)
TN (1) TN2009000323A1 (ru)
WO (1) WO2008092894A1 (ru)
ZA (1) ZA200904676B (ru)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL143266A0 (en) 1998-11-27 2002-04-21 Darwin Discovery Ltd Transforming growth factor-beta binding proteins and pharmaceutical compositions for increasing bone mineral content utilizing the same
CA2529623A1 (en) 2003-06-16 2005-02-17 Celltech R & D, Inc. Antibodies specific for sclerostin and methods for increasing bone mineralization
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
EP1981910B1 (en) * 2006-01-13 2013-06-26 A Chan Holding B.V. Method for identifying inhibitor of the glypican-sclerostin interaction
AU2008287426B2 (en) * 2007-08-10 2014-06-26 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
WO2009064944A2 (en) 2007-11-16 2009-05-22 Nuvelo, Inc. Antibodies to lrp6
AU2010207880B2 (en) * 2009-01-29 2012-03-29 Commonwealth Scientific Industrial Research Organisation Measuring G protein coupled receptor activation
ME02819B (me) 2010-05-14 2018-01-20 Amgen Inc Formulacije sa visokom koncentracijom antitijela
US8614190B2 (en) 2010-06-30 2013-12-24 Industrial Technology Research Institute Thermal responsive composition for treating bone diseases
EP2412724A1 (en) * 2010-07-29 2012-02-01 Centre National de la Recherche Scientifique (C.N.R.S) Regulation of Glypican 4 activity to modulate the fate of stem cells and uses thereof
KR20180129991A (ko) 2010-11-05 2018-12-05 노파르티스 아게 Ｉｌ-１７ 길항제를 사용한 류마티스성 관절염의 치료 방법
US9133272B2 (en) 2011-03-01 2015-09-15 Amgen Inc. Bispecific binding agents
EA029956B1 (ru) 2011-03-25 2018-06-29 Эмджен Инк. Кристаллы антител против склеростина и составы на их основе
EP2699261B1 (en) 2011-04-19 2018-07-11 Amgen Inc. Method for treating osteoporosis
WO2012149246A1 (en) 2011-04-29 2012-11-01 Novartis Ag Methods of treating squamous cell carcinoma related applications
WO2013019954A1 (en) 2011-08-04 2013-02-07 Amgen Inc. Method for treating bone gap defects
KR20190120401A (ko) 2011-12-28 2019-10-23 암젠 인크 항스클레로스틴 항체의 이용을 통한 치조골 소실의 치료 방법
AU2013285488B2 (en) 2012-07-05 2018-03-22 Ucb Pharma S.A. Treatment for bone diseases
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014118705A1 (en) 2013-01-31 2014-08-07 Novartis Ag Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists
WO2014144817A2 (en) * 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
WO2015034330A1 (ko) * 2013-09-09 2015-03-12 가톨릭대학교 산학협력단 헬로퓨지농을 유효성분으로 포함하는 골질환 치료 또는 예방용 조성물
US10077316B2 (en) 2013-12-27 2018-09-18 National University Corporation, Kochi University Esophageal cancer marker and use thereof
US20170009228A1 (en) * 2014-01-13 2017-01-12 Imperial Innovations Limited Biological materials and therapeutic uses thereof
WO2015106311A1 (en) * 2014-01-17 2015-07-23 Minomic International Ltd. Cell surface prostate cancer antigen for diagnosis
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
US11143659B2 (en) 2015-01-27 2021-10-12 Arterez, Inc. Biomarkers of vascular disease
WO2016208754A1 (ja) * 2015-06-24 2016-12-29 学校法人慶應義塾 抗グリピカン－１－免疫抗原受容体
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
EP3496744A1 (en) 2016-08-08 2019-06-19 Amgen Inc. Method of improving connective tissue attachment using anti-sclerostin antibodies
TWI667253B (zh) * 2016-12-30 2019-08-01 博晟生醫股份有限公司 重組多肽、核酸分子及其組合物以及製造、使用之方法
SG11202008206TA (en) 2018-03-30 2020-09-29 Amgen Inc C-terminal antibody variants
CN110499285A (zh) * 2018-05-17 2019-11-26 西安组织工程与再生医学研究所 Alpl基因在制备预防和/或治疗低碱性磷酸酶症的产品中的应用
CN112584823A (zh) * 2018-06-22 2021-03-30 纽约哥伦比亚大学理事会 用于治疗颞颌关节退化的缓释组成物及方法
KR20210043607A (ko) 2018-08-10 2021-04-21 암젠 인크 항체 제약 제형의 제조 방법
CN109734795B (zh) * 2019-01-17 2022-07-12 武汉明德生物科技股份有限公司 人Lrp4抗原、人Lrp4抗体检测试剂盒及其制备方法与应用
WO2020163876A1 (en) * 2019-02-08 2020-08-13 The Regents Of The University Of California Compositions and methods involving layilin
CN114630677A (zh) 2019-08-12 2022-06-14 安进公司 抗硬骨素抗体配制品
CN112656806B (zh) * 2020-12-24 2022-08-26 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 多配体蛋白聚糖4的siRNA序列在抑制犬瘟热病毒复制中的应用
CN113913463B (zh) * 2021-09-19 2023-08-18 郭保生 抑制sost基因表达的重组质粒及其骨靶向重组腺相关病毒与应用
WO2023114930A1 (en) * 2021-12-15 2023-06-22 The George Washington University Compositions for and methods of improving directed evolution of biomolecules
CN114984225B (zh) * 2022-06-22 2024-02-02 中山大学附属第八医院（深圳福田） hsa_circ_0005773在防治间充质干细胞衰老及骨关节炎中的应用
CN117169521A (zh) * 2023-08-25 2023-12-05 暨南大学附属第一医院（广州华侨医院） 一种种植体周围炎质谱负离子模式代谢组学生物标志物及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2008304C (en) * 1989-01-31 2001-03-27 Craig S. Hill Assay for bone alkaline phosphatase
AR028256A1 (es) * 2000-03-16 2003-04-30 Amgen Inc Moleculas similares a receptores il-17 y usos de las mismas
ATE452906T1 (de) * 2000-04-13 2010-01-15 Thomas N Wight Therapeutische zusammenfassungen und verfahren zur modulierung von v3, eine isoform von versican
AU2002258592A1 (en) * 2001-03-23 2002-11-25 The Burnham Institute Compositions and methods for modulating bone mineral deposition
JP4662714B2 (ja) * 2002-03-01 2011-03-30 セルテック アール アンド ディー インコーポレイテッド 骨密度を増減させる方法
US7169559B2 (en) * 2002-05-13 2007-01-30 Fonterra Corporate Research and Development Ltd. LDL receptor-related proteins 1 and 2 and treatment of bone or cartilage conditions
JP4660471B2 (ja) * 2003-03-14 2011-03-30 セルテック アール アンド ディー， インコーポレイテッド ＴＧＦβ結合タンパク質のリガンドおよびその使用
BRPI0414446A (pt) * 2003-09-18 2006-11-14 Genmab As métodos para triar um agente terapêutico, para a supressão da sequência de polinucleotìdeo, para o tratamento de um cáncer não dependente de esteróide, para triar a ligação de um agente especificamente a um polinucleotìdeo e para determinar se um paciente está em risco de desenvolver ou ter um cáncer não dependente de esteróide, composição farmacêutica, usos de um agente terapêutico, de uma molécula anti-sentido ou de uma célula que expressa e/ou contém a molécula anti-sentido, de pelo menos uma das proteìnas de membrana imunogênicas, fragmentos, derivados ou homólogos destas ou de uma célula que contém e/ou que expressa pelo menos uma das proteìnas de membranas imunogênicas ou fragmentos, derivados ou homólogos destas e de um agente ou anticorpo, agente, e, kit para identificar um paciente em risco de desenvolver ou ter cáncer não dependente de esteróide
US8461155B2 (en) * 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
WO2005070965A2 (en) * 2004-01-21 2005-08-04 Five Prime Therapeutics, Inc. Pharmaceutical compositions containing antagonists to lrp4, lrp8 or megalin for treatment of diseases
US7476512B2 (en) * 2004-02-27 2009-01-13 The General Hospital Corporation Methods of identifying dermal papilla cells
CN101027390B (zh) * 2004-07-22 2012-12-12 卫材R&D管理有限公司 Lrp4/Corin多巴胺能神经元祖细胞标志物
WO2007021003A1 (ja) * 2005-08-18 2007-02-22 Eisai R & D Management Co., Ltd. ドーパミン産生ニューロン増殖前駆細胞マーカーＮａｔｏ３
EP1981910B1 (en) * 2006-01-13 2013-06-26 A Chan Holding B.V. Method for identifying inhibitor of the glypican-sclerostin interaction

Also Published As

Publication number Publication date
US20130164284A1 (en) 2013-06-27
IL199834A0 (en) 2010-04-15
TN2009000323A1 (en) 2010-12-31
CN101616684A (zh) 2009-12-30
AU2008209713B2 (en) 2012-01-19
AU2008209713A1 (en) 2008-08-07
NZ578235A (en) 2012-05-25
BRPI0807205A2 (pt) 2014-07-22
WO2008092894A1 (en) 2008-08-07
ZA200904676B (en) 2010-04-28
EP2114435A1 (en) 2009-11-11
US20120003219A1 (en) 2012-01-05
CA2675639A1 (en) 2008-08-07
KR20090115133A (ko) 2009-11-04
JP2010526766A (ja) 2010-08-05
US20100028335A1 (en) 2010-02-04
MA31156B1 (fr) 2010-02-01
MX2009008096A (es) 2009-08-07

Similar Documents

Publication Publication Date Title
EA200901031A1 (ru) Модуляторы склеростин-связывающих партнеров для лечения костных расстройств
MY145070A (en) Imidazolothiazole compounds for the treatment of disease
EA200601760A1 (ru) Тетрагидроиндазольные модуляторы каннабиноидов
EA201071243A1 (ru) Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом
MA31167B1 (fr) Inhibiteurs de l'activite de akt
EA201000559A1 (ru) Композиции и способы применения антител к склеростину
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MX2009005935A (es) Compuestos biciclicos y su uso como anti-diabeticos.
EA200702455A1 (ru) Модуляторы индоламин 2,3-диоксигеназы и способы их применения
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201071100A1 (ru) Пиридилсодержащие ингибиторы передачи сигнала через белок hedgehog
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
BRPI0519496A2 (pt) processo para preparar um composto ou uma composiÇço, e, composiÇço
ECSP088854A (es) Moduladores bencimidazolicos de vr1
EA200970737A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
EA200602221A1 (ru) Новое применение пептидных соединений для лечения боли при тригеминальной невралгии
EA200800835A1 (ru) Циклопропиламины в качестве модуляторов рецептора гистамина н
EA200802072A1 (ru) Ликопин для лечения нарушения обмена веществ
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
ATE458480T1 (de) Hexahydro-cyclooctyl-pyrazol-cannabinoid- modulatoren
EA200971141A1 (ru) Соединения, активирующие теломеразу, и способы их применения
MY186456A (en) Quinazoline carboxamide azetidines
IL193479A0 (en) Modulators of muscarinic receptors